These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 18987148)

  • 1. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.
    Sather DN; Armann J; Ching LK; Mavrantoni A; Sellhorn G; Caldwell Z; Yu X; Wood B; Self S; Kalams S; Stamatatos L
    J Virol; 2009 Jan; 83(2):757-69. PubMed ID: 18987148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.
    Sather DN; Stamatatos L
    Vaccine; 2010 May; 28 Suppl 2():B8-12. PubMed ID: 20510750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.
    Mikell I; Stamatatos L
    PLoS One; 2012; 7(11):e49610. PubMed ID: 23152926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
    Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
    PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of the earliest cross-neutralizing antibody response to HIV-1.
    Mikell I; Sather DN; Kalams SA; Altfeld M; Alter G; Stamatatos L
    PLoS Pathog; 2011 Jan; 7(1):e1001251. PubMed ID: 21249232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.
    Gray ES; Taylor N; Wycuff D; Moore PL; Tomaras GD; Wibmer CK; Puren A; DeCamp A; Gilbert PB; Wood B; Montefiori DC; Binley JM; Shaw GM; Haynes BF; Mascola JR; Morris L
    J Virol; 2009 Sep; 83(17):8925-37. PubMed ID: 19553335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.
    Kraft Z; Derby NR; McCaffrey RA; Niec R; Blay WM; Haigwood NL; Moysi E; Saunders CJ; Wrin T; Petropoulos CJ; McElrath MJ; Stamatatos L
    J Virol; 2007 Jun; 81(12):6402-11. PubMed ID: 17392364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the maturation of neutralizing antibodies on human immunodeficiency virus (HIV) envelope evolution in HIV-infected subjects.
    Zhao J; Nie J; Jiao Y; Li L; Zhang T; Liu Q; Huang W; Wu H; Wang Y
    Infect Genet Evol; 2016 Mar; 38():82-89. PubMed ID: 26706846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses.
    Ranasinghe S; Soghoian DZ; Lindqvist M; Ghebremichael M; Donaghey F; Carrington M; Seaman MS; Kaufmann DE; Walker BD; Porichis F
    J Virol; 2015 Dec; 90(5):2208-20. PubMed ID: 26656715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
    Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
    Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
    Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
    Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.
    Blish CA; Nguyen MA; Overbaugh J
    PLoS Med; 2008 Jan; 5(1):e9. PubMed ID: 18177204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
    Gray ES; Madiga MC; Hermanus T; Moore PL; Wibmer CK; Tumba NL; Werner L; Mlisana K; Sibeko S; Williamson C; Abdool Karim SS; Morris L;
    J Virol; 2011 May; 85(10):4828-40. PubMed ID: 21389135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.